Linzagolix

• Description:

  Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  508.42

• Molecular Formula:

  C22H15F3N2O7S

• Notes:

  Research use only, not for human use.

• Receptor:

  Antibacterial

• CAS Number:

  935283-04-8